Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MULTILINEAGE DYSPLASIA WITH OR WITHOUT RING SIDEROBLASTS
27 ledna, 2021 8:38 pmAuthor(s): Abhishek Mangaonkar, Terra Lasho, Christy Finke, Naseema Gangat, et al. Abstract: PF501 Session topic: 10. Myelodysplastic syndromes...
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
27 ledna, 2021 8:38 pmAuthor(s): Paolo Strati, Guillermo Garcia-Manero, Tapan Kadia, Gautam Borthakur, et al. Abstract: PS1251 Session topic: 10. Myelodysplastic syndromes...
DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION
27 ledna, 2021 8:38 pmAuthor(s): Begoña Pedrote, Jose Francisco Falantes, Estrella Carrillo, Cristina Calderon-Cabrera, et al. Abstract: PF496 Session topic: 10. Myelodysplastic...
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
27 ledna, 2021 8:38 pmAuthor(s): Carolina Lazzarino, Marcelo Iastrebner, Jacqueline Gonzalez, Jorge Arbelbide, et al. Abstract: PS1259 Session topic: 10. Myelodysplastic syndromes...
MYELODYSPLASTICKÝ SYNDROM – VÝBĚR Z EDUKAČNÍCH SDĚLENÍ A POSTERŮ
27 ledna, 2021 8:38 pmPráce publikované formou edukačních sdělení 1. FACING THE CHALLENGE: NOVEL TREATMENT OPTIONS FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES Nové léčebné...
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
27 ledna, 2021 8:38 pmAuthor(s): Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, et. al. Abstract: S801 Session topic: 21. Aggressive Non-Hodgkin...
AN UPDATED ANALYSIS OF JULIET, A GLOBAL PIVOTAL PHASE 2 TRIAL OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
27 ledna, 2021 8:38 pmAuthor(s): Peter Borchmann, Constantine S. Tam, Ulrich Jäger Abstract: S799 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical...
RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
27 ledna, 2021 8:38 pmAuthor(s): Frank Morschhauser, Nathan H. Fowler, Pierre Feugier, et. al Abstract: S154 Session topic: 20. Indolent Non-Hodgkin lymphoma...
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
27 ledna, 2021 8:38 pmAuthor(s): Laurie H. Sehn, Manali Kamdar, Alex F. Herrera, et. al. Abstract: S802 Session topic: 21. Aggressive Non-Hodgkin...
FINAL ANALYSIS OF THE AHL201 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA
27 ledna, 2021 8:38 pmAuthor(s): Olivier Casasnovas, Pauline Brice, Reda Bouabdallah, et. al Abstract: S110 Session topic: 17. Hodgkin lymphoma – Clinical...